Oragenics Chases Vaccine for Niche Markets
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine
Serendipity is the word Alan Joslyn uses to describe the meeting and eventual acquisition of a Gainesville-based biotech firm. “It’s not every... Read More
Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Biotech Firm Picks Gainesville As It Seeks COVID-19 Vaccine
Noachis Terra Inc., a new biotechnology company that will focus its efforts on the development of a vaccine for COVID-19 announced its... Read More
